Gorodetski, Boris
Becker, Philipp Hendrik
Baur, Alexander Daniel Jacques
Hartenstein, Alexander
Rogasch, Julian Manuel Michael
Furth, Christian
Amthauer, Holger
Hamm, Bernd
Makowski, Marcus
Penzkofer, Tobias http://orcid.org/0000-0001-9591-8575
Funding for this research was provided by:
Berlin Institute of Health (Clinician Scientist Grant)
Charité - Universitätsmedizin Berlin
Article History
Received: 16 February 2022
Accepted: 13 July 2022
First Online: 15 September 2022
Declarations
:
: Institutional Review Board approval was not required because of the retrospective nature of the study.
: Written informed consent was waived by the Institutional Review Board.
: BG, PHB, AH, JMMR, CF, and MM declare that they have no competing interests. ADJB declares no conflicts of interest directly related to this work. He has received payments as a speaker for b·e·imaging GmbH as well as Takeda Pharmaceutical Company Limited. HA received lecture fees from Pfizer, Sirtex, Novartis, GE, Norgine, and travel expenses from Terumo. BH received grant money from the following companies or non-profit organisations to the Dept of Radiology: Abbott, AbbVie, Ablative Solutions, Accovion, Achaogen Inc., Actelion Pharmaceuticals, ADIR, Aesculap, Agios Pharmaceuticals, INC, AGO, AIF Arbeitsgemeinschaft industrieller Forschungsvereinigungen, AIO: Arbeitsgemeinschaft Internistische Onkologie, Alexion Pharmaceuticals, Amgen, AO Foundation, Arena Pharmaceuticals, ARMO Biosciences, Inc., art photonics GmbG Berlin, Ascelia Pharma AB, ASR Advanced sleep research, Astellas, AstraZeneca, BARD, Bayer Healthcare, Bayer Schering Pharma, Bayer Vital, BBraun (Sponsoring a workshop), Berlin-Brandenburger Centrum für Regenerative Therapien (BCRT), Berliner Krebsgesellschaft, Biotronik, Bioven, BMBF, Boehring Ingelheimer, Boston Biomedical Inc., Boston Scientific Medizintechnik GmbH, BRACCO Group, Brainsgate, Bristol-Myers Squibb, Calithera Bioschiences UK, Cantargia AB, Medcion Village, Cascadian 7 Therapeutics, Inc., Celgene, CELLACT Pharma, Celldex, Therapeutics, CeloNova BioSciences, Charité research organisatin GmbH, Chiltern, CLOVIS ONCOLOGY, INC., Covance, CRO Charite, CUBIST, CureVac AG, Tübingen, Curis, Daiichi Sankyo, Dartmouth College, Hanover, NH, USA, DC Devices, Inc. USA, Delcath Systems, Dermira Inc. Deutsche Krebshilfe, Deutsche Rheuma Liga, Deutsches Zentrum für Luft- und Raumfahrt e.V., DFG, Dr. Falk Pharma GmbH, DSM Nutritional Products AG, Dt. Stiftung für Herzforschung, Dynavax, Eisai Ltd., European Knowledge Centre, Mosquito Way, Hatfield, Eli Lilly and Company Ltd. EORTC, Epizyme, INC., Essex Pharma, EU Programmes, Euroscreen S.A., Ferring Pharmaceuticals A/S, Fibrex Medical Inc., Focused Ultrasound Surgery Foundation, Fraunhofer Gesellschaft, Galena Biopharma, Galmed Research and Development Ltd., Ganymed, GE, Genentech Inc., Genmab A/S, Genzysme Europe B.V., GETNE (Grupo Espanol de Tumores Neuroendocrinos), Gilead Sciences, Inc, Glaxo Smith Kline, Glycotope GmbH, Berlin, Goethe Uni Frankfurt, Guerbet, Guidant Europe NV, Halozyme, Hewlett Packard GmbH, Holaira Inc. ICON (CRO), Idera Pharmaceuticals, Inc., Ignyta, Inc. Immunomedics Inc., Immunocore, Incyte, INC Research, Innate Pharma, InSightec Ltd., Inspiremd, inVentiv Health Clinical UK Ltd., Inventivhealth, IOMEDICO, IONIS, IPSEN Pharma, IQVIA, ISA Therapeutics, Isis Pharmaceuticals Inc., ITM Solucin GmbH, Jansen-Cilag GmbH, Kantar Health Gmbh (CRO), Kartos Therapeutics, Inc., Karyopharm Therapeutics, Inc., Kendle/ MorphoSys Ag, Kite Pharma, Kli Fo Berlin Mitte, La Roche, Land Berlin, Lilly GmbH, Lion Biotechnology, Lombard Medical, Loxo Oncology, Inc., LSK BioPartners; USA, Lundbeck GmbH, Lux Biosciences, LYSARC, MacroGenics, MagForce, MedImmune Inc., MedImmune Limited, Medpace, Medpace Germany GmbH (CRO), MedPass (CRO), Medronic, Medtraveö GmbH, Merck, Merrimack Pharmaceuticals Inc., MeVis Medical Solutions AG, Millennium Pharmaceuticals Inc., miRagen Boukider, Mologen, Monika Kutzner Stiftung, MSD Sharp, Nektar Therapeutics, NeoVacs SA, Newlink Genentics Corporation, Nexus Oncology, NIH, Novartis, novocure, Nuvisan, Ockham oncology, Odonate Therapeutics San Diego, OHIRC Kanada, Orion Corporation Orion Pharma, OSE Immunotherapeutics, Parexel CRO Service, Perceptive, Pfizer GmbH, PharmaCept GmbH, Pharma Mar, Pharmaceutical Research Associates GmbH (PRA), Pharmacyclics Inc., Philipps, PIQUR Therapeutics Ltd., Pluristem, PneumRX. Inc, Portola Pharmaceuticals, PPD (CRO), PRAint, Premier-research, Provectus Biopharmaceuticals, Inc., psi-cro, Pulmonx International Sàrl, Quintiles GmbH, Regeneron Pharmaceuticals, Inc., Respicardia, Roche, Samsung, Sanofi, sanofis-aventis S.A., Schumacher GmbH (Sponsoring a workshop), Seattle Genetics, Servier (CRO), SGS Life Science Services (CRO), Shire Human Genetic Therapies, Siemens, Silena Therapeutics, SIRTEX Medical Europe GmbH, Spectranetics GmbH, Spectrum Pharmaceuticals, Stiftung Charite/BIH, St. Jude Medical, Stiftung Wolfgang Schulze, Symphogen, Taiho Oncology, Inc., Taiho Pharmaceutical Co., Target Pharma Solutions Inc., TauRx Therapeutics Ltd., Terumo Medical Corporation, Tesaro, tetec-ag, TEVA, Theorem, Theradex, Theravance, Threshold Pharmaceuticals Inc., TNS Healthcare GmbH, Toshiba, UCB Pharma, Uni München, Uni Tübingen, Vaccibody A.S., 8 VDI/VDE, Vertex Pharmaceuticals Incorporated, Virtualscopis LLC, winicker-norimed, Wyeth Pharma, Xcovery Holding Company, Zukunftsfond Berlin (TSB). TP was supported by Berlin Institute of Health (Clinician Scientist Grant, Platform Grant) and reports research agreements (no personal payments, outside of submitted work) with AGO, Aprea AB, ARCAGY-GINECO, Astellas Pharma Global Inc. (APGD), Astra Zeneca, Clovis Oncology, Inc., Dohme Corp, Holaira, Incyte Corporation, Karyopharm, Lion Biotechnologies, Inc., MedImmune, Merck Sharp, Millennium Pharmaceuticals, Inc., Morphotec Inc., NovoCure Ltd., PharmaMar S.A. and PharmaMar USA, Inc., Roche, Siemens Healthineers, and TESARO Inc.